Compare NEON & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEON | IGC |
|---|---|---|
| Founded | 1997 | 2005 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5M | 27.7M |
| IPO Year | 1994 | 2005 |
| Metric | NEON | IGC |
|---|---|---|
| Price | $0.89 | $0.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $5.25 |
| AVG Volume (30 Days) | 104.9K | ★ 344.2K |
| Earning Date | 05-13-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 37.88 | ★ 59.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,108,000.00 | $1,271,000.00 |
| Revenue This Year | $72.74 | N/A |
| Revenue Next Year | $28.94 | $13.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $0.24 |
| 52 Week High | $26.95 | $0.50 |
| Indicator | NEON | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 52.40 | 41.25 |
| Support Level | $0.73 | $0.24 |
| Resistance Level | $1.05 | $0.30 |
| Average True Range (ATR) | 0.07 | 0.01 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 82.26 | 36.00 |
Neonode Inc provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. Its machine perception solutions are based on the MultiSensing technology platform. The company also offers optical sensing solutions for contactless touch and gesture sensing. It markets and sells its solutions mainly to customers in the automotive sector, along with other markets such as office equipment, industrial automation, medical, military, and avionics. Geographically, the company operates in Japan, South Korea, Germany, Sweden, China, and other regions, with a majority of its revenue generated from Japan.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.